ClinicalTrials.gg
CompletedNCT05568706RSVHRUpdated Aug 19, 2026Results posted

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

A Phase 2 interventional study of EDP-938 and Placebo in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
Largest of 10
187 · median 81
Started
2022
the only one that year
Phase 2
4 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one has the largest enrollment, is the only one that started in 2022, is one of 4 in phase 2, and was the 8th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications after RSV infection.

03

Conditions studied

  • RSV Infection

Keywords

  • High Risk, Respiratory Syncytial Virus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least one of the following conditions that predispose them to complications after RSV infection:

    1. Age ≥65 years
    2. Congestive heart failure (CHF)
    3. Asthma
    4. (COPD)
  • The subject has a new onset of any of the following symptom(s) or worsening of pre-existing symptom(s) consistent with a respiratory tract infection no more than 72 hours prior to the administration of the first dose of study drug: feeling feverish, headache, neck pain, fatigue, loss of appetite, interrupted sleep, body aches, sore throat, nasal congestion, cough, cough with phlegm, wheezing, or short of breath.
  • The subject reports at least 2 of the following symptoms, one of which must be reported as at least 'moderate' severity: cough, cough with phlegm, wheezing, or short of breath
  • The subject has tested positive for RSV infection using a NAAT (polymerase chain reaction [PCR] or other) on a nasal/nasopharyngeal swab sample.
  • A woman of who is sexually active with a male must agree to use two effective methods of from the date of Screening until 30 days after her last dose of study drug.
  • A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • The subject has an anticipated need for hospitalization within 24 hours of signing the Study ICF
  • The subject has concomitant respiratory infections that are viral (other than RSV but including influenza), bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days prior to signing the Study ICF
  • The subject has a SARS-CoV-2 test result that is positive within 28 days prior to signing the Study ICF
  • The subject has with spirometry results (obtained within 1 year prior to signing the Study ICF) ≤35%
  • The subject has a known positive infection, active hepatitis A virus infection, chronic virus infection, and/or current virus (HCV) infection; subjects with a history of HCV infection who have achieved a documented sustained virologic response 12 weeks after completion of HCV therapy may be enrolled.
  • The subject has any of the following cardiac conditions: any congenital heart disease, congenital long syndrome, or any clinical manifestation resulting in QT interval prolongation
  • The subject has status
  • The subject is living in institutional care or assisted living facility and is also receiving acute care management for any respiratory condition; Note: Independent living apartments are not considered institutional care or assisted living facility
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    EDP-938

    EDP-938 800 mg, once daily

    Drug: EDP-938

  • Placebo comparator
    Placebo

    Matching placebo, once daily

    Drug: Placebo

Interventions

  • Subjects took EDP-938 once daily for 5 days

  • DrugPlacebo

    Subjects took matching placebo, once daily for 5 days

06

What researchers measure

Primary outcomes

  1. Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms

    Resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution of LRTD symptoms is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  2. Time to Complete Resolution of LRTD Symptoms for the mITT Population

    Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  3. Time to Complete Resolution of LRTD Symptoms for the HR3 Population

    Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

Secondary outcomes

  1. Time to Resolution of LRTD Symptoms and 2 Systemic Symptoms

    Resolution of LRTD and 2 Systemic Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) and each of the 2 systemic symptoms (feeling fever and fatigue/tiredness) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero or 1; Higher scores indicate worse outcomes (greater symptom intensity and greater impact on daily functioning). Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  2. Time to Resolution of All RSV Symptoms

    Resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQ Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  3. Time to Complete Resolution of All RSV Symptoms for the mITT Population

    Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  4. Time to Complete Resolution of All RSV Symptoms for the HR3 Population

    Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  5. Change From Baseline in Severity of RSV LRTD Symptoms

    The RiiQ Infection Intensity Scale assesses 4 symptoms of LRTD (cough, shortness of breath, wheezing, and expectoration) on a scale from 0 (absent) to 3 (severe). The composite LRTD Score is the average of all 4 individual item scores.

    Time frame: Day 1 through Day 33

  6. Change From Baseline for Impact Scale

    The RiiQ Impact Scale assesses daily activities (7 items), emotions (4 items), and social relationships (5 items) on a scale of 0 (no impact) to 3 (extreme impact). The composite Impact Score is the average of all 16 individual item scores.

    Time frame: Day 1 through Day 33

  7. Time to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms

    Resolution of Symptoms is defined as the first of two consecutive timepoints where each of the RSV symptoms (4 LRTD symptoms \[cough, short of breath, wheezing, coughing up phlegm \[sputum\]\], 2 URTD symptoms \[nasal congestion and sore throat\], 2 Systemic symptoms \[feeling feverish and fatigue\[tiredness\]\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  8. Time to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships

    Resolution of No or Mild Impact of RSV is defined as the first of two consecutive timepoints where each of the 3 impact Scale Scores (daily activities, emotions and social relationships) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  9. Percentage of Participants With Post-baseline RSV-related Complications

    Time frame: Day 1 through Day 33

  10. Time to Improvement in RSV Disease

    Time to Improvement is defined as the time from first dose to first timepoint where the response assessed by PGI-C is 'Much better'. Time to Improvement is calculated as: date/time of Improvement - date/time of first timepoint.

    Time frame: Day 1 through Day 33

  11. Change From Baseline for Health-Related Quality of Life

    Assessed by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire; 5 dimensions (mobility, taking care of yourself, usual activities, pain/discomfort, and anxiety/depression) are scored on 5 levels from 1 (full health) to 5 (extreme disability). An index score is derived based on the 5 reported levels where 1.0 represents full health and 0.0 the worst possible health.

    Time frame: Day 1 through Day 33

  12. Time to Return to Usual Health

    Time to return to usual health is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Health is 'Yes'. Time to return to usual health is calculated as: date/time of return to usual health - date/time of response to 'Yes'.

    Time frame: Day 1 through Day 33

  13. Time to Return to Usual Activities

    Time to return to usual activities is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Activities is 'Yes'. Time to return to usual activities is calculated as: date/time of return to usual activities - date/time of first response to 'Yes'.

    Time frame: Day 1 through Day 33

  14. Percentage of Subjects Requiring Hospitalization for RSV or Other Causes

    Time frame: Day 1 through Day 33

  15. Duration of Hospitalization for RSV or Other Causes

    Time frame: Day 1 through Day 33

  16. All-cause Mortality

    Time frame: Day 1 through Day 33

  17. RSV RNA Viral Load Change From Baseline for the mITT Population

    Time frame: Days 3, 5, 9, and 14

  18. Change in Infectious RSV Viral Load Over Time

    Time frame: Up to Day 14

  19. Proportion of Subjects With RSV RNA Viral Load Target Not Detected (TND) for the mITT Population

    Time frame: Days 1, 3, 5, 9 and 14

  20. Time to RSV RNA Viral Load TND for the mITT Population

    Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.

    Time frame: Day 1 through Day 14

  21. Plasma PK Concentrations of EDP-938

    Time frame: Up to Day 5

  22. Safety as Measured by Frequency of Adverse Events (AEs)

    Number of subjects experiencing any Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 33

  23. Time to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population

    PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

    Time frame: Day 1 through Day 33

  24. Incidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population

    Incidence was defined as the number of subjects with new antibiotic, bronchodilators, inhaled corticosteroids or oxygen use

    Time frame: Day 1 through Day 33

  25. Incidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population

    Incidence was defined as the number of subjects with unscheduled medically attended visits for RSV infection or other causes.

    Time frame: Day 1 through Day 33

07

Results

Posted Aug 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneEDP-938Placebo
Started12364
Completed11660
Not completed74
Withdrew: Adverse event01
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject62
Withdrew: Death01

Outcome measures

PrimaryTime to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms

Resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution of LRTD symptoms is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms
daysEDP-938Placebo
Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms5.0 (4.0 to 7.0)4.1 (3.0 to 5.9)
PrimaryTime to Complete Resolution of LRTD Symptoms for the mITT Population

Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of LRTD Symptoms for the mITT Population
DaysEDP-938Placebo
Time to Complete Resolution of LRTD Symptoms for the mITT Population12.5 (11.2 to 15.3)13.0 (9.6 to 19.0)
PrimaryTime to Complete Resolution of LRTD Symptoms for the HR3 Population

Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of LRTD Symptoms for the HR3 Population
DaysEDP-938Placebo
Time to Complete Resolution of LRTD Symptoms for the HR3 Population12.0 (10.0 to 15.2)15.0 (9.9 to 20.0)
SecondaryTime to Resolution of LRTD Symptoms and 2 Systemic Symptoms

Resolution of LRTD and 2 Systemic Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) and each of the 2 systemic symptoms (feeling fever and fatigue/tiredness) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero or 1; Higher scores indicate worse outcomes (greater symptom intensity and greater impact on daily functioning). Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Resolution of LRTD Symptoms and 2 Systemic Symptoms
daysEDP-938Placebo
Time to Resolution of LRTD Symptoms and 2 Systemic Symptoms5.0 (4.1 to 6.0)5.0 (3.0 to 6.0)
SecondaryTime to Resolution of All RSV Symptoms

Resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQ Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Resolution of All RSV Symptoms
daysEDP-938Placebo
Time to Resolution of All RSV Symptoms5.9 (5.0 to 6.8)5.0 (4.8 to 7.1)
SecondaryTime to Complete Resolution of All RSV Symptoms for the mITT Population

Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of All RSV Symptoms for the mITT Population
DaysEDP-938Placebo
Time to Complete Resolution of All RSV Symptoms for the mITT Population13.8 (12.0 to 16.1)16.0 (12.0 to 23.0)
SecondaryTime to Complete Resolution of All RSV Symptoms for the HR3 Population

Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of All RSV Symptoms for the HR3 Population
DaysEDP-938Placebo
Time to Complete Resolution of All RSV Symptoms for the HR3 Population12.2 (11.1 to 16.1)18.9 (13.0 to 24.7)
SecondaryChange From Baseline in Severity of RSV LRTD Symptoms

The RiiQ Infection Intensity Scale assesses 4 symptoms of LRTD (cough, shortness of breath, wheezing, and expectoration) on a scale from 0 (absent) to 3 (severe). The composite LRTD Score is the average of all 4 individual item scores.

Time frame:
Day 1 through Day 33
Reported as:
Mean · RiiQ Scale Score
Change From Baseline in Severity of RSV LRTD Symptoms
RiiQ Scale ScoreEDP-938Placebo
Day 2-0.320 ± 0.5362-0.315 ± 0.5056
Day 3-0.411 ± 0.5411-0.513 ± 0.6168
Day 5-0.815 ± 0.6400-0.811 ± 0.5830
Day 7-1.052 ± 0.6785-1.022 ± 0.7043
Day 9-1.165 ± 0.7136-1.086 ± 0.7427
Day 14-1.376 ± 0.6785-1.327 ± 0.6699
Day 33-1.439 ± 0.7911-1.473 ± 0.7378
SecondaryChange From Baseline for Impact Scale

The RiiQ Impact Scale assesses daily activities (7 items), emotions (4 items), and social relationships (5 items) on a scale of 0 (no impact) to 3 (extreme impact). The composite Impact Score is the average of all 16 individual item scores.

Time frame:
Day 1 through Day 33
Reported as:
Mean · Impact Scale Score
Change From Baseline for Impact Scale
Impact Scale ScoreEDP-938Placebo
Day 2-0.314 ± 0.5568-0.229 ± 0.6998
Day 3-0.415 ± 0.6554-0.434 ± 0.7848
Day 5-0.640 ± 0.6847-0.592 ± 0.7620
Day 7-0.864 ± 0.8279-0.707 ± 0.8685
Day 9-1.001 ± 0.9005-0.786 ± 0.9597
Day 14-1.001 ± 0.8945-0.940 ± 0.8526
Day 33-1.154 ± 0.8800-1.130 ± 0.8767
SecondaryTime to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms

Resolution of Symptoms is defined as the first of two consecutive timepoints where each of the RSV symptoms (4 LRTD symptoms \[cough, short of breath, wheezing, coughing up phlegm \[sputum\]\], 2 URTD symptoms \[nasal congestion and sore throat\], 2 Systemic symptoms \[feeling feverish and fatigue\[tiredness\]\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms
daysEDP-938Placebo
Time to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms5.8 (5.0 to 6.2)5.0 (4.0 to 6.1)
SecondaryTime to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships

Resolution of No or Mild Impact of RSV is defined as the first of two consecutive timepoints where each of the 3 impact Scale Scores (daily activities, emotions and social relationships) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships
daysEDP-938Placebo
Time to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships3.0 (2.0 to 3.0)2.0 (1.9 to 4.0)
SecondaryPercentage of Participants With Post-baseline RSV-related Complications
Time frame:
Day 1 through Day 33
Reported as:
Count of participants · Participants
Percentage of Participants With Post-baseline RSV-related Complications
ParticipantsEDP-938Placebo
Percentage of Participants With Post-baseline RSV-related Complications53
SecondaryTime to Improvement in RSV Disease

Time to Improvement is defined as the time from first dose to first timepoint where the response assessed by PGI-C is 'Much better'. Time to Improvement is calculated as: date/time of Improvement - date/time of first timepoint.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Improvement in RSV Disease
daysEDP-938Placebo
Time to Improvement in RSV Disease5.0 (4.0 to 6.0)6.0 (4.0 to 7.0)
SecondaryChange From Baseline for Health-Related Quality of Life

Assessed by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire; 5 dimensions (mobility, taking care of yourself, usual activities, pain/discomfort, and anxiety/depression) are scored on 5 levels from 1 (full health) to 5 (extreme disability). An index score is derived based on the 5 reported levels where 1.0 represents full health and 0.0 the worst possible health.

Time frame:
Day 1 through Day 33
Reported as:
Mean · EQ-5D 5L Score
Change From Baseline for Health-Related Quality of Life
EQ-5D 5L ScoreEDP-938Placebo
Day 50.108 ± 0.18360.083 ± 0.1407
Day 90.207 ± 0.20300.152 ± 0.1679
Day 140.210 ± 0.21420.169 ± 0.1549
Day 330.233 ± 0.19510.182 ± 0.1544
SecondaryTime to Return to Usual Health

Time to return to usual health is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Health is 'Yes'. Time to return to usual health is calculated as: date/time of return to usual health - date/time of response to 'Yes'.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Return to Usual Health
daysEDP-938Placebo
Time to Return to Usual Health8.0 (6.1 to 10.0)8.0 (6.0 to 10.7)
SecondaryTime to Return to Usual Activities

Time to return to usual activities is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Activities is 'Yes'. Time to return to usual activities is calculated as: date/time of return to usual activities - date/time of first response to 'Yes'.

Time frame:
Day 1 through Day 33
Reported as:
Median · days
Time to Return to Usual Activities
daysEDP-938Placebo
Time to Return to Usual Activities6.0 (5.0 to 7.0)6.5 (5.0 to 8.0)
SecondaryPercentage of Subjects Requiring Hospitalization for RSV or Other Causes
Time frame:
Day 1 through Day 33
Reported as:
Count of participants · Participants
Percentage of Subjects Requiring Hospitalization for RSV or Other Causes
ParticipantsEDP-938Placebo
Percentage of Subjects Requiring Hospitalization for RSV or Other Causes23
SecondaryDuration of Hospitalization for RSV or Other Causes
Time frame:
Day 1 through Day 33
Reported as:
Median · days
Duration of Hospitalization for RSV or Other Causes
daysEDP-938Placebo
Duration of Hospitalization for RSV or Other Causes3.5 (3.0 to 4.0)7.0 (5.0 to 11.0)
SecondaryAll-cause Mortality
Time frame:
Day 1 through Day 33
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsEDP-938Placebo
All-cause Mortality01
SecondaryRSV RNA Viral Load Change From Baseline for the mITT Population
Time frame:
Days 3, 5, 9, and 14
Reported as:
Least squares mean · RSV viral load (log10 copies/mL)
RSV RNA Viral Load Change From Baseline for the mITT Population
RSV viral load (log10 copies/mL)EDP-938Placebo
Day 3-1.199 ± 0.1757-0.803 ± 0.2417
Day 5-2.153 ± 0.2107-1.561 ± 0.2895
Day 9-3.698 ± 0.2289-3.401 ± 0.3072
Day 14-4.424 ± 0.1985-4.326 ± 0.2635
SecondaryChange in Infectious RSV Viral Load Over Time
Time frame:
Up to Day 14
Reported as:
Mean · RSV Viral Load (log10 TCID50/ml)
Change in Infectious RSV Viral Load Over Time
RSV Viral Load (log10 TCID50/ml)EDP-938Placebo
Day 3-0.590 ± 1.4789-0.517 ± 1.5516
Day 5-0.656 ± 1.4389-0.836 ± 1.7683
Day 9-0.662 ± 1.4442-0.937 ± 1.6041
Day 14-0.664 ± 1.4534-0.908 ± 1.6033
SecondaryProportion of Subjects With RSV RNA Viral Load Target Not Detected (TND) for the mITT Population
Time frame:
Days 1, 3, 5, 9 and 14
Reported as:
Count of participants · Participants
Proportion of Subjects With RSV RNA Viral Load Target Not Detected (TND) for the mITT Population
ParticipantsEDP-938Placebo
Day 143
Day 3145
Day 5276
Day 95526
Day 147036
SecondaryTime to RSV RNA Viral Load TND for the mITT Population

Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.

Time frame:
Day 1 through Day 14
Reported as:
Median · Days
Time to RSV RNA Viral Load TND for the mITT Population
DaysEDP-938Placebo
Time to RSV RNA Viral Load TND for the mITT Population8.0 (7.9 to 12.8)11.9 (8.0 to 13.0)
SecondaryPlasma PK Concentrations of EDP-938
Time frame:
Up to Day 5
Reported as:
Median · ng/mL
Plasma PK Concentrations of EDP-938
ng/mLEDP-938
Visit 1 - Postdose847.00 (0.0 to 5200.0)
Visit 2 - Predose926.00 (0.0 to 5060.0)
Visit 3 - Predose979.50 (0.0 to 4040.0)
Early Disc/EOS883.00 (366.0 to 1400.0)
SecondarySafety as Measured by Frequency of Adverse Events (AEs)

Number of subjects experiencing any Treatment-Emergent Adverse Events (TEAEs)

Time frame:
Up to Day 33
Reported as:
Count of participants · Participants
Safety as Measured by Frequency of Adverse Events (AEs)
ParticipantsEDP-938Placebo
Safety as Measured by Frequency of Adverse Events (AEs)2716
SecondaryTime to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population

PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population
DaysEDP-938Placebo
Time to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population9.0 (8.0 to 10.0)10.9 (9.0 to 15.0)
SecondaryIncidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population

Incidence was defined as the number of subjects with new antibiotic, bronchodilators, inhaled corticosteroids or oxygen use

Time frame:
Day 1 through Day 33
Reported as:
Count of participants · Participants
Incidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population
ParticipantsEDP-938Placebo
Incidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population166
SecondaryIncidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population

Incidence was defined as the number of subjects with unscheduled medically attended visits for RSV infection or other causes.

Time frame:
Day 1 through Day 33
Reported as:
Count of participants · Participants
Incidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population
ParticipantsEDP-938Placebo
Incidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population84
Post-hocTotal RSV Symptom Score by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale for the HR3 Population

The RiiQ Infection Intensity Scale assesses 4 lower respiratory, 2 upper respiratory, and 7 systemic symptoms on a scale of 0 (absent) to 3 (severe). The composite Total Symptom Score is the average of all 13 individual item scores.

Time frame:
Day 1 through Day 33
Reported as:
Least squares mean · MMRM adjusted LS mean score
Total RSV Symptom Score by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale for the HR3 Population
MMRM adjusted LS mean scoreEDP-938Placebo
Day 21.213 ± 0.04201.209 ± 0.0561
Day 31.072 ± 0.04641.061 ± 0.0622
Day 50.713 ± 0.04460.723 ± 0.0597
Day 70.452 ± 0.04680.569 ± 0.0620
Day 90.320 ± 0.04430.470 ± 0.0586
Day 140.194 ± 0.03690.331 ± 0.0493
Day 330.083 ± 0.02240.095 ± 0.0302
Post-hocTotal RSV Symptom Score by RiiQ Scale for the mITT Population

The RiiQ Infection Intensity Scale assesses 4 lower respiratory, 2 upper respiratory, and 7 systemic symptoms on a scale of 0 (absent) to 3 (severe). The composite Total Symptom Score is the average of all 13 individual item scores.

Time frame:
Day 1 through Day 33
Reported as:
Least squares mean · MMRM adjusted LS mean score
Total RSV Symptom Score by RiiQ Scale for the mITT Population
MMRM adjusted LS mean scoreEDP-938Placebo
Day 21.208 ± 0.03771.172 ± 0.0514
Day 31.049 ± 0.04281.001 ± 0.0587
Day 50.695 ± 0.03970.686 ± 0.0543
Day 70.456 ± 0.04150.517 ± 0.0563
Day 90.332 ± 0.03870.425 ± 0.0523
Day 140.211 ± 0.03330.300 ± 0.0454
Day 330.069 ± 0.01830.078 ± 0.0253
Post-hocRSV RNA Viral Load Change From Baseline for the HR3 Population
Time frame:
Days 3, 5, 9, and 14
Reported as:
Least squares mean · RSV viral load (log10 copies/mL)
RSV RNA Viral Load Change From Baseline for the HR3 Population
RSV viral load (log10 copies/mL)EDP-938Placebo
Day 3-1.079 ± 0.2096-0.522 ± 0.2827
Day 5-1.880 ± 0.2407-1.226 ± 0.3233
Day 9-3.437 ± 0.2697-2.904 ± 0.3510
Day 14-4.046 ± 0.2475-3.865 ± 0.3149
Post-hocTime to Complete Resolution of Total Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score for the mITT Population

Complete resolution of total RiiQ scale score (Q1-29) is defined as the first of two consecutive timepoints where the score of each of the 29 questions is zero. Time to complete resolution (days) is calculated as: date/time of complete resolution - date/time of first dose.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of Total Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score for the mITT Population
DaysEDP-938Placebo
Time to Complete Resolution of Total Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score for the mITT Population15.3 (12.2 to 19.5)18.9 (13.1 to 28.0)
Post-hocTime to Complete Resolution of Total RiiQ Scale Score for the HR3 Population

Complete resolution of total RiiQ scale score (Q1-29) is defined as the first of two consecutive timepoints where the score of each of the 29 questions is zero. Time to complete resolution (days) is calculated as: date/time of complete resolution - date/time of first dose.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Complete Resolution of Total RiiQ Scale Score for the HR3 Population
DaysEDP-938Placebo
Time to Complete Resolution of Total RiiQ Scale Score for the HR3 Population13.8 (11.9 to 19.9)21.0 (13.1 to NA)
Post-hocTime to Resolution of RSV Infection Symptoms by PGI-S Scale Score for the HR3 Population

PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.

Time frame:
Day 1 through Day 33
Reported as:
Median · Days
Time to Resolution of RSV Infection Symptoms by PGI-S Scale Score for the HR3 Population
DaysEDP-938Placebo
Time to Resolution of RSV Infection Symptoms by PGI-S Scale Score for the HR3 Population9.0 (8.0 to 11.0)10.9 (9.0 to 16.0)
Post-hocProportion of Subjects With RSV RNA Viral Load TND for the HR3 Population
Time frame:
Days 1, 3, 5, 9 and 14
Reported as:
Count of participants · Participants
Proportion of Subjects With RSV RNA Viral Load TND for the HR3 Population
ParticipantsEDP-938Placebo
Day 143
Day 3144
Day 5225
Day 94418
Day 145227
Post-hocTime to RSV RNA Viral Load TND for the HR3 Population

Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.

Time frame:
Day 1 through Day 14
Reported as:
Median · Days
Time to RSV RNA Viral Load TND for the HR3 Population
DaysEDP-938Placebo
Time to RSV RNA Viral Load TND for the HR3 Population8.0 (7.8 to 13.0)12.9 (8.0 to 13.1)

Adverse events

Collected over Adverse event data was collected beginning on Day 1 and concluded at the End-of-Study (EOS) visit on Day 33.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EDP-9380/115 (0%)2/121 (1.7%)27/121 (22.3%)
Placebo1/60 (1.7%)4/65 (6.2%)16/65 (24.6%)
Most frequent serious events
Most frequent serious events
EventEDP-938Placebo
PneumoniaInfections and infestations0/1211/65
Pneumonia bacterialInfections and infestations0/1211/65
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1211/65
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1211/65
Cardiac failure chronicCardiac disorders0/1211/65
Systemic inflammatory response syndromeGeneral disorders0/1211/65
Renal impairmentRenal and urinary disorders0/1211/65
InfluenzaInfections and infestations1/1210/65
AsthmaRespiratory, thoracic and mediastinal disorders1/1210/65
Most frequent other events
Showing 10 of 46
Most frequent other events
EventEDP-938Placebo
DiarrhoeaGastrointestinal disorders4/1211/65
NauseaGastrointestinal disorders1/1212/65
AsthmaRespiratory, thoracic and mediastinal disorders2/1211/65
AstheniaGeneral disorders2/1210/65
Glomerular filtration rate decreasedInvestigations2/1210/65
DysgeusiaNervous system disorders2/1210/65
DyspepsiaGastrointestinal disorders0/1211/65
Faeces softGastrointestinal disorders1/1211/65
HaemorrhoidsGastrointestinal disorders0/1211/65
BronchitisInfections and infestations0/1211/65

Baseline characteristics

Modified Intent-to-Treat (mITT) population: all randomized subjects positively diagnosed with RSV using the central RT-qPCR test who receive at least one dose of assigned study drug.

Age, Continuous
Age, Continuous(years)EDP-938PlaceboTotal
Mean68.0 ± 14.2968.1 ± 15.4668.0 ± 14.66
Sex: Female, Male
Sex: Female, Male(Participants)EDP-938PlaceboTotal
Female6945114
Male461561
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EDP-938PlaceboTotal
Hispanic or Latino7229101
Not Hispanic or Latino433174
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EDP-938PlaceboTotal
American Indian or Alaska Native101
Asian426
Native Hawaiian or Other Pacific Islander112
Black or African American11213
White9854152
More than one race000
Unknown or Not Reported011
08

Study locations

84 sites
  • Voyage Medical
    Tempe, Arizona 85282-2455, United States
  • UCSF Fresno
    Fresno, California 93701, United States
  • Torrance Clinical Research Institute
    Lomita, California 90717, United States
  • Downtown LA Research Center Inc - ClinEdge - PPDS
    Los Angeles, California 90017, United States
  • Allianz Research Institute Inc
    Westminster, California 92683, United States
  • Allianz Research Institute - Colorado
    Aurora, Colorado 80014, United States
  • Bay Pines VA Healthcare System
    Bay Pines, Florida 33744, United States
  • C&A Clinical Trials Corp
    Cape Coral, Florida 33990, United States
  • Beautiful Minds Clinical Research Center
    Cutler Bay, Florida 33157, United States
  • Dinamo Research & Diagnostic center, LLC
    Hialeah, Florida 33015, United States
  • I.H.S Health LLC
    Kissimmee, Florida 34741, United States
  • Dynamic Medical Research, LLC
    Miami, Florida 33144, United States
  • Floridian Research Institute
    Miami, Florida 33179-2537, United States
  • Orlando VA Healthcare System
    Orlando, Florida 32827, United States
  • Ormond Beach Clinical Research
    Ormond Beach, Florida 32174, United States
  • CDC Research Institute, LLC
    Port Saint Lucie, Florida 34952, United States
  • Research Bay, Inc.
    Tampa, Florida 33607, United States
  • Santos Research Center
    Tampa, Florida 33615, United States
  • Covenant Pulmonary Criticial Care and Research Ins
    East Point, Georgia 30344, United States
  • Snake River Research
    Idaho Falls, Idaho 83404, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Global Health Institute
    Syracuse, New York 13210-1685, United States
  • Progressive Medicine of the Triad, LLC
    Winston-Salem, North Carolina 27103, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 43617, United States
  • IMA Clinical Research - Austin - PPDS
    Austin, Texas 78704-7507, United States
  • Valley Institute of Research
    Fort Worth, Texas 76164-9041, United States
  • HDH Research, Inc.
    Houston, Texas 77022, United States
  • Metroplex Pulmonary and Sleep Medicine Center-4833 Medical Center Dr Unit 6B
    McKinney, Texas 75069, United States
  • SMS Clinical Research, LLC
    Mesquite, Texas 75149, United States
  • Eastside Research Associates
    Redmond, Washington 98052, United States
  • Instituto Medico Platense
    La Plata, Buenos Aires 1900, Argentina
  • Centro de Investigaciones Medica Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • Clinica Privada Independencia
    Munro, Buenos Aires B1605, Argentina
  • Consultorios Médicos Dr. Doreski
    Buenos Aires, Ciudad Autónoma de BuenosAires C1426ABP, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, Córdoba Province 5800, Argentina
  • Instituto Del Buen Aire
    Santa Fe, Santa Fe Province 3000, Argentina
  • Clinica Mayo de U.M.C.B. S.R.L
    San Miguel de Tucumán, Tucumán Province T4000NWB, Argentina
  • Multiprofile Hospital for Active Treatment Puls AD - PPDS
    Blagoevgrad, Blagoevgrad 2700, Bulgaria
  • Medical Center For Life EOOD
    Burgas, Burgas 8000, Bulgaria
  • Diagnostic Consultative Center-1-Sevlievo EOOD
    Sevlievo, Gabrovo 5400, Bulgaria
  • Medical Center Zdrave-1 OOD
    Kozloduy, Kozloduy 3320, Bulgaria
  • Medical Center Hera - Kyustendil EOOD
    Kyustendil, Kyustendil 2500, Bulgaria
  • Specialized Hospital for Active Treatment of Pulmonary Diseases
    Troyan Municipality, Lovech 5600, Bulgaria
  • Diagnostic Consultative Center 1- Lom EOOD
    Lom, Montana 3600, Bulgaria
  • Medical Center Hera EOOD, Montana
    Montana, Montana 3400, Bulgaria
  • Specialized Hospital for Active Treatment of Pulmonary Diseases- Pernik EOOD
    Pernik, Pernik 2300, Bulgaria
  • Medical Center Prolet EOOD
    Rousse, Ruse 7002, Bulgaria
  • Medical Center Hipocrena
    Sevlievo, Sevlievo 5400, Bulgaria
  • Medical Center Hera EOOD
    Sofia, Sofia 1202, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sofiamed OOD
    Sofia, Sofia 1750, Bulgaria
  • Medical Center Sanador M EOOD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Medical Centre Pratia Clinic EOOD Varna
    Varna, Varna, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, Veliko Tarnovo 5000, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
    Haskovo, 6305, Bulgaria
  • Medical Center Neuromedix EOOD
    Veliko Tarnovo, 5006, Bulgaria
  • Servicios de Salud IPS Suramericana S.A.S. - IPS Sura Industriales Medellin
    Medellín, Antioquia 50021, Colombia
  • Clinica de la Costa Ltda - PPDS
    Barranquilla, Atlántico 080020, Colombia
  • Clínica Universidad De la Sabana
    Chía, Cundinamarca 250001, Colombia
  • Fundacion Centro de Investigaciones Clinicas IPS Cardiomet Pereira
    Pereira, Risaralda Department 660003, Colombia
  • Oinsamed S.A.S - Clinica Misericordia
    Barranquilla, 080020, Colombia
  • Fundacion Centro de Investigacion Clinica CIC
    Medellín, 050021, Colombia
  • MUDr. Jakub Strincl, s.r.o.
    Liberec, Liberec Region 460 14, Czechia
  • Res Medica s.r.o.
    Nový Knín, 262 03, Czechia
  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
  • Instituto Jalisciense de Investigacion Clinica SA de CV
    Guadalajara, Jalisco 44100, Mexico
  • CICUM San Miguel
    Guadalajara, Jalisco 44160, Mexico
  • Centro de Investigación Clinica Médica y Farmacoló
    Guadalajara, Jalisco 44690, Mexico
  • Hospital Civil Fray Antonio Alcalde
    Guadalajara, Jalisco 45235, Mexico
  • Centro de Atención e Investigación Médica S.A. - México - CAIMED - PPDS
    Mexico City, Mexico City 06760, Mexico
  • Accelerium, S. de R.L. de C.V. - PPDS
    Monterrey, Nuevo León 31000, Mexico
  • Camacho Ortiz, Adrian
    Monterrey, Nuevo León, Mexico
  • Centro de Alta Especialidad Dr. Rafael Lucio
    Veracruz, Veracruz 91020, Mexico
  • FAICIC
    Veracruz, Veracruz 91700, Mexico
  • Oaxaca Site Management Organization - Clinic - OSMO - PPDS
    Oaxaca City, 68000, Mexico
  • Centrum Medyczne PROFAMILIA
    Lodz, Łódź Voivodeship 91-463, Poland
  • Plucna ambulancia Hrebenar, s.r.o.
    Spišská Nová Ves, 052 01, Slovakia
  • Newtown Clinical Research Centre
    Johannesburg, 2001, South Africa
  • Be Part Yoluntu Centre
    Paarl, 7646, South Africa
  • Hospital General Universitario Dr. Balmis
    Alicante, Alicante 03010, Spain
  • Centro de salud Cabra Matrona Antonia Mesa Fernández
    Cabra, Cordoba 14940, Spain
  • CHUS - H. Clinico U. de Santiago
    Santiago de Compostela, 15706, Spain
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jun 2025, 30 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 30 months is above that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Nov 29, 2022
Primary completionActual
Jun 23, 2025
CompletionActual
Jun 23, 2025
Results first posted
Aug 19, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05568706
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Nov 29, 2022
Primary completion
Jun 23, 2025
Completion
Jun 23, 2025
Results posted
Aug 19, 2026
Last update
Aug 19, 2026

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion